The financials
Mesoblast Limited by the numbers
Mesoblast Limited (MESO) reported revenue of $51M in H1 2026 (quarter ended December 31, 2025), up 1415% from the same quarter a year earlier. That came with a gross margin of 85% and net loss of $40M. For the full year FY2025, revenue was $17M (+191% year on year) and net income −$102M.
| Income statement | H1 2026 | H1 2024 | Change |
|---|---|---|---|
| Revenue | $51M | $3.4M | +1415% |
| Gross profit | $44M | n/a | n/a |
| Net income | −$40M | −$33M | n/a |
| Diluted EPS | −$0.03 | −$0.04 | n/a |
Biotechnology
The closest names by size in the same industry